Geratherm Medical AG: Geratherm Medical report preliminary (unaudited) 2019 business figures

Geratherm Medical AG / Key word(s): Preliminary Results
Geratherm Medical AG: Geratherm Medical report preliminary (unaudited) 2019 business figures

31-March-2020 / 17:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of an insider information pursuant to article 17 of MAR
transmitted by DGAP - a service of EQS Group AG

Geratherm Medical report preliminary (unaudited) 2019 business figures

- Sales 19.9 million EUR -7.8 %

- EBITDA 2,577 k EUR -8.0 %

- EBIT 1,273 k EUR -36.0 %

- EAT 546 k EUR -52.7 %

- Result per share 11 cents

- Dividend proposal 25 cents per unit share

- Conversion of sales of apoplex medical to the entire contract term (IFRS delimitation) results in one-off strain in sales (-205 k EUR) and impact on earnings (-568 k EUR, incl. deferred tax burden amounting to 314 k EUR)

- Strong sales and earnings growth expected for 2020

Geratal, March 31, 2020 - Geratherm Medical record for the 2019 fiscal year a drop in sales of -7.8 % to 19.9 million EUR on a consolidated basis. The Healthcare Diagnostic core business (66.0 % of the group sales) could report a solid growth of + 5.1 %. The one-off special charges were due to apoplex medical, where the present sales had to be delimited according to IFRS over the entire term of the hospital contracts concluded. The one-off effect led to a decline in sales of 205 k EUR and an impact on earnings of 568 k EUR, of which 313 k EUR are for the passive deferred tax liabilities for development services. Due to product conversions, the LMT Medical subsidiary showed postponements of orders to the 2020 fiscal year resulting in a decline in sales of 1,409 k EUR and an impact on earnings of 467 EUR on group level.

The 2019 special charges should not occur again in this form for the 2020 fiscal year. Due to the Corona pandemic, Geratherm Medical had a strong start into the new fiscal year. The clinical thermometer production is being increased by 30 %. At present the demand cannot be satisfied. There is evidence that the pulmonary function of patients after a hospital stay due to Corona could be limited. Geratherm Respiratory sell pulmonary function measuring instruments for diagnosing late effects. In the first quarter the sales rose by 30 %. At present there is an increased number of incoming orders from China. We can expect that other countries will follow. The new factory building in Bad Kissingen provides the respective production capacities.

Geratherm Medical expect significantly higher reported sales and earnings for the 2020 fiscal year.

The detailed annual report will be published on April 23, 2020.

Geratherm Medical AG
Firmensitz: Fahrenheitstraße 1, 99331 Geratal
Registergericht: Amtsgericht Jena, HRB 111272
Vorstand: Dr. Gert Frank
Aufsichtsratsvorsitzender: Dipl.-Kfm. Rudolf Bröcker
Tel. 036205/98 0
E-Mail: info@geratherm.com
www.geratherm.com

Short company profil:
Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MR Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.

31-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de